Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
where to buy fat dildos? - LovToyLand.com
Popular Articles

Hosting Olympics Boosts Host Country's Medal Haul Before And Afterwards
[Why Great Britain"s success in Beijing could have been anticipated and why it should continue beyond 2012
diet pills
American Academy Of Dermatology Commends Reclassification Of Tanning Beds As Carcinogenic
The American Academy of Dermatology (Academy) commends the International Agency for Research on Cancer (IARC) for its re-categorization of indoor tanning devices as carcinogenic to humans. This classification places indoor tanning in the highest cancer risk category afforded by this international agency, which is a division of the World Health Organization (WHO).
News of the day
Blood-Borne Molecule Helps Regulate Blood-Vessel Integrity
Although maintaining the integrity of blood vessel walls is essential for life, well-controlled temporary leakage of blood contents through the walls of blood vessels into the tissues is a hallmark of inflammation. Although the molecule S1P is known to act on the cells that line blood vessels (endothelial cells) to regulate the permeability of blood vessel walls, the in vivo of SIP in this process remains unknown, and whether it has a role in inflammation has not been determined. In a new study, Shaun Coughlin and colleagues, at UCSF, San Francisco, have shed light on these issues, revealing that mice that lack S1P selectively in plasma (the liquid component of blood) have increased leakage from the blood vessels in response to a variety of stimuli, including inflammatory ones. As the leakage was reversed by treatment with either S1P-containing red blood cells or an agonist for the protein to which SIP binds, the authors conclude that S1P in the blood regulates blood-vessel integrity and prevents potentially lethal decreases in blood volume after exposure to leak-inducing stimuli.
Health Insurance

Watson Pharmaceuticals Receives FDA Approval For Fruit And Cinnamon Flavored Coated Nicotine Gums

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration to market its over-the-counter Nicotine Polacrilex Gum USP, 2 mg and 4 mg strengths in the coated fruit and cinnamon flavors. Nicotine Polacrilex Gum coated fruit and cinnamon flavors are the generic equivalent of GlaxoSmithKline Consumer Healthcare"s Nicorette Fruit Chill(R) and Cinnamon Surge(TM) Coated gums, which are used as an aid to smoking cessation. The market for over-the-counter nicotine gum had annual sales of over $305 million for the twelve months ending March 2009, according to IRI sales data. Watson will make the products available to customers immediately. About Watson Pharmaceuticals, Inc. Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women"s Health and Nephrology/Medical. Forward-Looking Statement Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson"s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson"s current expectations depending upon a number of factors affecting Watson"s business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson"s products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; patents and other intellectual property rights held by third parties; and other risks and uncertainties detailed in Watson"s periodic public filings with the Securities and Exchange Commission, including but not limited to Watson"s Annual Report on Form 10-K for the year ended December 31, 2008. Nicorette Fruit Chill(R) is a registered trademark of GlaxoSmithKline Consumer Healthcare, L.P. Nicorette Cinnamon Surge(TM) is a trademark of GlaxoSmithKline Consumer Healthcare, L.P. Watson Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009